227 related articles for article (PubMed ID: 3161945)
41. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody.
Schenkman S; Güther ML; Yoshida N
J Immunol; 1986 Sep; 137(5):1623-8. PubMed ID: 2943798
[TBL] [Abstract][Full Text] [Related]
42. Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions.
Ng YC; Schifferli JA; Walport MJ
Clin Exp Immunol; 1988 Mar; 71(3):481-5. PubMed ID: 2968204
[TBL] [Abstract][Full Text] [Related]
43. Interaction of human monomeric C3b with its receptor (complement receptor type 1, CR1) on neutrophils. Evidence for negative cooperativity.
Porteu F; Halbwachs-Mecarelli L
J Biol Chem; 1988 Apr; 263(11):5091-7. PubMed ID: 2965698
[TBL] [Abstract][Full Text] [Related]
44. Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component.
Lambris JD; Lao Z; Oglesby TJ; Atkinson JP; Hack CE; Becherer JD
J Immunol; 1996 Jun; 156(12):4821-32. PubMed ID: 8648130
[TBL] [Abstract][Full Text] [Related]
45. Modulation of neutrophil expression of C3b receptors (CR1) by soluble monomeric human C3b.
Porteu F; Mir A; Halbwachs-Mecarelli L
Eur J Immunol; 1987 May; 17(5):629-35. PubMed ID: 2953614
[TBL] [Abstract][Full Text] [Related]
46. The binding of immune complexes by the erythrocyte complement receptor 1 (CR1).
Pascual M; Schifferli JA
Immunopharmacology; 1992; 24(2):101-6. PubMed ID: 1473961
[TBL] [Abstract][Full Text] [Related]
47. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.
Kalli KR; Hsu PH; Bartow TJ; Ahearn JM; Matsumoto AK; Klickstein LB; Fearon DT
J Exp Med; 1991 Dec; 174(6):1451-60. PubMed ID: 1836011
[TBL] [Abstract][Full Text] [Related]
48. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
Daha MR; Kok DJ; Van Es LA
Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the human erythrocyte complement receptor CR1 (C3b receptor) by epitope mapping.
Prohaska R; Adolf GR
Immunobiology; 1987 Jan; 174(1):93-106. PubMed ID: 2437016
[TBL] [Abstract][Full Text] [Related]
50. Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces.
Carreno MP; Labarre D; Maillet F; Jozefowicz M; Kazatchkine MD
Eur J Immunol; 1989 Nov; 19(11):2145-50. PubMed ID: 2480904
[TBL] [Abstract][Full Text] [Related]
51. Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: phagocytosis, transfer, and associations with CR1.
Craig ML; Waitumbi JN; Taylor RP
J Immunol; 2005 Mar; 174(5):3059-66. PubMed ID: 15728520
[TBL] [Abstract][Full Text] [Related]
52. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
Jelezarova E; Vogt A; Lutz HU
Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
[TBL] [Abstract][Full Text] [Related]
53. Competition for binding sites on C3b by CR1, CR2, MCP, factor B and factor H.
Farries TC; Seya T; Harrison RA; Atkinson JP
Complement Inflamm; 1990; 7(1):30-41. PubMed ID: 2138950
[TBL] [Abstract][Full Text] [Related]
54. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
55. Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity.
Ezzell JL; Parker CJ
Scand J Immunol; 1992 Jul; 36(1):79-87. PubMed ID: 1535452
[TBL] [Abstract][Full Text] [Related]
56. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
57. Membrane-bound C4b interacts endogenously with complement receptor CR1 of human red cells.
Kinoshita T; Medof ME; Hong K; Nussenzweig V
J Exp Med; 1986 Nov; 164(5):1377-88. PubMed ID: 2430040
[TBL] [Abstract][Full Text] [Related]
58. Studies on the mechanism of C3b inhibition of immune complex induced C1 activation.
Ziccardi RJ
Mol Immunol; 1988 Dec; 25(12):1339-46. PubMed ID: 3237217
[TBL] [Abstract][Full Text] [Related]
59. In vivo binding of circulating immune complexes by C3b receptors (CR1) of transfused erythrocytes.
Inada Y; Kamiyama M; Kanemitsu T; Ikegami H; Watanabe K; Clark WS; Asai Y
Ann Rheum Dis; 1989 Apr; 48(4):287-94. PubMed ID: 2523692
[TBL] [Abstract][Full Text] [Related]
60. Complement-opsonized IgG antibody/dsDNA immune complexes bind to CR1 clusters on isolated human erythrocytes.
Taylor RP; Pocanic F; Reist C; Wright EL
Clin Immunol Immunopathol; 1991 Nov; 61(2 Pt 1):143-60. PubMed ID: 1833104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
